



**Suitability Petition
Completeness Assessment Correspondence**

Newcastle Bioscience, LLC
999 Vanderbilt Beach Road, Suite 200
Naples, FL 34108
Attn: Gene Nakagawa

Sent via email to: gene@newcastlebio.com

Docket No. FDA-2024-P-1870

Dear Gene Nakagawa:

This is in reference to your petition received on April 15, 2024, by the U.S. Food and Drug Administration (FDA or Agency), requesting permission, in accordance with 21 C.F.R. §314.93(b), to submit an Abbreviated New Drug Application (ANDA) for the following drug product: Escitalopram Oxalate Orally Disintegrating Tablets, 5 mg, 10 mg, 15 mg and 20 mg. The petition was examined for initial completeness (i.e., Completeness Assessment) under CFR 10.30 and the Agency has made a threshold determination that the petition is complete.

This petition is subject to the provisions of the Generic Drugs User Fee Amendments of 2022 (GDUFA III) whereby any suitability petitions submitted in FY 2024-2027 will receive a goal date of 6 months after the completeness assessment. The GDUFA goal date for review of this petition is November 6, 2024.

If you have any questions, contact ANDAFiling@fda.hhs.gov.

A copy of this letter will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely,

{See appended electronic signature page}

Rosanne Pagaduan, Pharm.D.
Supervisory Pharmacist
Division of Filing Review
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



Rosanne
Pagaduan

Digitally signed by Rosanne Pagaduan

Date: 5/06/2024 01:38:22PM

GUID: 5407741f000a111ad49784616594fb72